CJC 1295 is a tetrasubstituted peptide hormone that is made up of a 30 amino acid chain. This chemical is primarily used by the body, to act as a growth hormone releasing hormone or GHRH analog. This synthetic chemical was developed by ConjuChem from Canada and is now used in laboratories worldwide, to further investigate how this chemical can affect animal tissues when regularly administered to active tissues.
One of the advantages that appear when administering CJC 1295 in animals rather than traditional rHGH or GHRH chemicals is that the animal’s body is able to bioconjugate CJC 1295 with serum albumin. This can be used to increase the therapeutic window and half life of the product while protecting groups of surrounding amino acids that would normally be susceptible to enzymatic degradation.
Maleimido derviates of human growth hormone releasing factor were bioconjugated and synthesized to mimic human albumin serums ex vivo for the sake of study.
All of these human serum albumin conjugates featured an enhanced stability for dipeptidylpeptidase-IV and were considered to be a growth hormone secretion in the anterior pituitary cells of rats where it was applied.
When these chemicals were applied to normal male rats the secretion of growth hormone was measured in the plasma. CJC 1295 was found to be the most effective in producing these effects and was selected for further pharmacokinetic evaluation where it was revealed it could develop reactions in the plasma beyond 72 hours.
A blot analysis of plasma from rats exposed to CJC 1295 revealed that the presence of this chemical caused an immunoreactive response that responded to the serum albumin after 15 minutes. This remained in the rat’s circulation for longer than 24 hours.
To better understand how growth deficiencies could be managed with the administration of growth hormone, mice that have GHRH gene ablation were administered injections of this analog, to stabilize their growth patterns.
CJC-1295 is used as a synthetic GHRH analog that was injected simultaneously with GHRH because it binds with selective albumin and extends the half-life of this response.
After receiving daily applications of this chemical combination, the mice returned to normal body weight and length.
Findings suggest that daily administration of CJC 1295 may be used in pharmaceutical settings, to help animals that are suffering from a deficiency in growth response maintain a normal body composition.
This study aimed to take advantage of growth hormone pulsatility when CJC 1295 was administered, to understand which secretion parameters would result in IGF-1 production.
The growth hormone pulsatility was assessed by taking blood samples every 20 minutes from animal test subjects and then taking samples every 12 hours for a week after the CJC 1295 injection was administered.
The growth hormone secretions in these animals increased after CJD 1295 was administered and the frequency of these pulses appeared to remain steady with base levels increasing overall.
CJC-1295 was found to increase the mean secretions of growth hormone while preserving the puslatility. This implies that increasing this pulse can increase IGF-1 with long term preparations used in patients that have ‘intact’ pituitary growth hormone secretion ability.
When using CJC 1295 for research purposes it is essential to get a version of this chemical that is designed for the type of work you plan to do. Different strengths and applications of this chemical are designed for different types of animals or applications, and you will need to plan accordingly. Given its use in research settings, all samples of CJC 1295 are designed to be sterile and prepared for research settings; you can contact the manufacturer if you are unsure.